Merck & Co. Inc. stock (US58933Y1055): Earnings beat and pipeline update drive investor interest

Merck & Co. Inc. stock rose after the pharma giant reported better?than?expected quarterly earnings and highlighted progress in its oncology and vaccine pipeline.

Merck & Co. Inc. stock moved higher after the U.S. pharmaceutical company posted stronger?than?expected first?quarter 2026 results and reiterated confidence in its growth drivers, including the cancer drug Keytruda and its vaccine portfolio, according to a company press release and earnings call transcript dated May 1, 2026.

On the Nasdaq, Merck & Co. Inc. shares traded at 138.45 USD on May 1, 2026, up roughly 3.2% intraday following the release, according to Nasdaq.com as of May 1, 2026. The move reflects investor relief that the company continues to offset patent?related headwinds with volume growth in key brands and a deepening late?stage pipeline, analysts noted in follow?up commentary.

For the three months ended March 31, 2026, Merck & Co. Inc. reported adjusted earnings per share of 2.48 USD, ahead of the consensus estimate of 2.39 USD, according to Reuters as of May 1, 2026. Revenue rose 7% year?over?year to 16.7 billion USD, driven by continued demand for Keytruda and growth in vaccines such as Gardasil and pneumococcal products.

Management maintained its full?year 2026 adjusted EPS guidance of 9.80–10.10 USD, while raising the midpoint of its revenue outlook to 67.5 billion USD, according to the same earnings materials. The company also confirmed plans to return capital to shareholders through dividends and share repurchases, with a 5% increase in the quarterly dividend announced alongside the results.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co., Inc.
• Sector/industry: Pharmaceuticals
• Headquarters/country: Kenilworth, New Jersey, United States
• Core markets: United States, Europe, Japan, China
• Key revenue drivers: Keytruda (pembrolizumab), Gardasil, Januvia, Janumet, vaccines and animal health
• Home exchange/listing venue: New York Stock Exchange (NYSE: MRK)
• Trading currency: USD

Merck & Co. Inc.: core business model

Merck & Co. Inc. operates as a global research?driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines, vaccines and animal health products. The company’s business model centers on high?margin branded therapies in oncology, diabetes, cardiovascular disease and infectious diseases, supported by a large?scale commercial infrastructure in the United States and key international markets.

Merck & Co. Inc. generates the majority of its revenue from human health products, with oncology and vaccines representing the largest segments. The company invests heavily in research and development, spending roughly 20–22% of sales on R&D in recent years, according to its annual reports and investor presentations. This R&D intensity underpins a broad late?stage pipeline that includes next?generation immuno?oncology agents, mRNA?based vaccines and targeted therapies for rare diseases.

For U.S. investors, Merck & Co. Inc. is notable as a large?cap dividend payer with a long?standing presence on the NYSE and inclusion in major indices such as the S&P 500. The company’s U.S. operations contribute a significant share of consolidated revenue, and its products are widely reimbursed through Medicare, Medicaid and private payers, giving it deep exposure to the U.S. healthcare system.

Main revenue and product drivers for Merck & Co. Inc.

Keytruda, Merck & Co. Inc.’s PD?1 inhibitor, remains the single largest revenue driver, accounting for roughly 40% of total sales in 2025, according to company disclosures and analyst summaries. The drug is approved in multiple solid tumors and hematologic malignancies and continues to expand into earlier?line settings and combination regimens, which supports sustained volume growth even as pricing pressure and competition increase.

Beyond oncology, Merck & Co. Inc.’s vaccine portfolio is a key growth engine. Gardasil, the human papillomavirus (HPV) vaccine, and the pneumococcal vaccine Pneumovax 23 contribute substantial revenue, particularly in the United States and Europe. The company is also advancing next?generation HPV and respiratory syncytial virus (RSV) vaccines, which could further diversify its immunization business.

In diabetes and cardiovascular disease, Merck & Co. Inc. markets established brands such as Januvia and Janumet, which face generic competition but still generate meaningful cash flow. The company is selectively investing in newer assets, including cardiovascular and metabolic therapies, to offset patent expirations and maintain overall revenue stability.

Industry trends and competitive position

The global pharmaceutical industry is characterized by rising R&D costs, increasing regulatory scrutiny and pressure on drug pricing, especially in the United States. At the same time, demand for innovative oncology and vaccine products remains strong, driven by aging populations, higher cancer incidence and growing awareness of preventive medicine.

Within this landscape, Merck & Co. Inc. holds a leading position in immuno?oncology and vaccines, competing with companies such as Bristol?Myers Squibb, Roche, Pfizer and Moderna. The company’s ability to extend Keytruda’s lifecycle through new indications and combinations, while advancing a diversified pipeline, helps it maintain a relatively resilient competitive profile.

Conclusion

Merck & Co. Inc. stock has benefited from a solid first?quarter earnings beat and continued momentum in its oncology and vaccine franchises, reinforcing its role as a core large?cap pharma holding for many U.S. investors. The company’s diversified product portfolio, strong cash generation and commitment to shareholder returns provide a degree of stability, even as it navigates patent cliffs and competitive pressures.

At the same time, investors should remain mindful of risks such as pricing regulation, clinical trial setbacks and the eventual loss of exclusivity for Keytruda, which could weigh on future growth. For those considering Merck & Co. Inc., the stock may appeal as a relatively defensive exposure to the healthcare sector, but its valuation and sensitivity to regulatory and pipeline developments warrant careful monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.